Buprenorphine and its formulations: a comprehensive review
Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2022-08-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.37517 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825139358663966720 |
|---|---|
| author | Salomon Poliwoda Nazir Noor Jack S. Jenkins Cain W. Stark Mattie Steib Jamal Hasoon Giustino Varrassi Ivan Urits Omar Viswanath Adam M. Kaye Alan D Kaye |
| author_facet | Salomon Poliwoda Nazir Noor Jack S. Jenkins Cain W. Stark Mattie Steib Jamal Hasoon Giustino Varrassi Ivan Urits Omar Viswanath Adam M. Kaye Alan D Kaye |
| author_sort | Salomon Poliwoda |
| collection | DOAJ |
| description | Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations. |
| format | Article |
| id | doaj-art-e0d11ba0d6cb402a855ea7e7c2d44604 |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2022-08-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-e0d11ba0d6cb402a855ea7e7c2d446042025-02-11T20:30:34ZengOpen Medical PublishingHealth Psychology Research2420-81242022-08-01103Buprenorphine and its formulations: a comprehensive reviewSalomon PoliwodaNazir NoorJack S. JenkinsCain W. StarkMattie SteibJamal HasoonGiustino VarrassiIvan UritsOmar ViswanathAdam M. KayeAlan D KayeBuprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.https://doi.org/10.52965/001c.37517 |
| spellingShingle | Salomon Poliwoda Nazir Noor Jack S. Jenkins Cain W. Stark Mattie Steib Jamal Hasoon Giustino Varrassi Ivan Urits Omar Viswanath Adam M. Kaye Alan D Kaye Buprenorphine and its formulations: a comprehensive review Health Psychology Research |
| title | Buprenorphine and its formulations: a comprehensive review |
| title_full | Buprenorphine and its formulations: a comprehensive review |
| title_fullStr | Buprenorphine and its formulations: a comprehensive review |
| title_full_unstemmed | Buprenorphine and its formulations: a comprehensive review |
| title_short | Buprenorphine and its formulations: a comprehensive review |
| title_sort | buprenorphine and its formulations a comprehensive review |
| url | https://doi.org/10.52965/001c.37517 |
| work_keys_str_mv | AT salomonpoliwoda buprenorphineanditsformulationsacomprehensivereview AT nazirnoor buprenorphineanditsformulationsacomprehensivereview AT jacksjenkins buprenorphineanditsformulationsacomprehensivereview AT cainwstark buprenorphineanditsformulationsacomprehensivereview AT mattiesteib buprenorphineanditsformulationsacomprehensivereview AT jamalhasoon buprenorphineanditsformulationsacomprehensivereview AT giustinovarrassi buprenorphineanditsformulationsacomprehensivereview AT ivanurits buprenorphineanditsformulationsacomprehensivereview AT omarviswanath buprenorphineanditsformulationsacomprehensivereview AT adammkaye buprenorphineanditsformulationsacomprehensivereview AT alandkaye buprenorphineanditsformulationsacomprehensivereview |